Translate this page into:
Bidirectional association between vitiligo and melasma: A large-scale population-based study
Corresponding author: Dr. Shany Sherman, Division of Dermatology, Rabin Medical Center, Petah Tikva, Israel. shanyshnush@gmail.com
-
Received: ,
Accepted: ,
How to cite this article: Sherman S, Duskin-Bitan H, Agiv T, Bar D, Marom-Haham L, Levi A, et al. Bidirectional association between vitiligo and melasma: A large-scale population-based study. Indian J Dermatol Venereol Leprol. doi: 10.25259/IJDVL_1828_2024
Abstract
Background
The dual diagnosis of vitiligo and melasma and their association has hardly been studied.
Objective
To test our hypothesis of an independent bidirectional association between vitiligo and melasma.
Methods
A population-based study was conducted on 24,436 patients with vitiligo and 119,205 matched comparators. Both a retrospective cohort design and a nested case-control design were used, with the calculation of adjusted hazard ratios (HRs) and odds ratios (ORs).
Results
The incidence of melasma per 1000 person-years was 1.38 (95% CI 1.22-1.54) in the vitiligo group and 0.88 (95% CI 0.84-0.96) in the comparison group. Patients with vitiligo had a 60% increased risk of developing melasma regardless of hormonal treatment, phototherapy, and thyroid disorders (adjusted HR, 1.58; 95% CI, 1.35-1.86). The prevalence of pre-existing melasma was higher in patients with vitiligo than in matched comparators (0.9% vs. 0.5%, P<0.001). Melasma was associated with a 30% increase in the odds of developing vitiligo (adjusted OR 1.32; 95% CI 1.12-1.55), regardless of hydroquinone treatment.
Limitations
Retrospective data collection.
Conclusion
A bidirectional association between vitiligo and melasma was observed. Treatment strategies for individuals with a dual diagnosis warrant further investigation.
Keywords
Bidirectional association
control study
melasma
nested case
retrospective cohort study
vitiligo
Introduction
Vitiligo is a chronic autoimmune disease with a 0.5-2.0% prevalence.1 It is characterised by depigmentation of the skin due to the destruction of melanocytes by autoreactive lymphocytes. Its pathogenesis potentially involves genetic predisposition,2 oxidative stress,3 and melanocyte abnormalities.4 There is no long-term sustainable treatment.5,6 Available options that aim to stabilise vitiligo lesions and restore skin pigmentation include corticosteroids, calcineurin inhibitors, phototherapy, and FDA-approved immunomodulatory drugs such as topical Janus Kinase (JAK) inhibitors.7,8 Narrowband ultraviolet B (NBUVB) is the most common phototherapy, promoting melanocyte migration and increased melanin production.9,10
Melasma is a chronic skin disorder characterised by symmetric hyperpigmented patches, mainly on the face.11 It occurs predominantly in women (about 90%). Melasma is more common in darker skin types, affecting mainly individuals of Hispanic, African, and Middle Eastern origin.12 Exacerbating factors include UV exposure, pregnancy, hormonal treatments, and genetics.13 The pathogenesis involves melanocyte hyperactivation and increased melanin production following sun exposure, with solar elastosis seen in most patients.14
Vitiligo and melasma represent opposite pigmentation disorders. Both carry a significant psychosocial burden and require long-term treatment because of their high recurrence rates.5,11,15 Previous studies have examined treatments for both conditions,16,17 but none have explored their possible association, especially given that treatment for one condition may induce the onset of the other.
We aimed to test the hypothesis of an independent bidirectional association between vitiligo and melasma through a population-based study, based on observations of patients affected by both conditions.
Methods
Study design and data set
Two study designs were used. A retrospective cohort study was conducted to estimate the incidence of new-onset melasma in patients with pre-existing vitiligo, and a nested case-control study was conducted to estimate the prevalence of preceding melasma (exposure) in patients with incident vitiligo (outcome). Data were sourced from the largest of four health maintenance organisations in the country, which had 4,873,374 enrollments as of December 2023 (53% of the population). Dermatology consultations within Clalit Health Services (CHS) are offered across three main settings: during hospital admissions, in hospital-affiliated outpatient clinics, and in community-based primary care clinics staffed by independent board-certified dermatologists. While visits to family physicians and paediatricians are fully covered, community-based dermatology visits require only a minimal quarterly co-payment (approximately 10 USD) and do not necessitate a referral. This streamlined and affordable access has led to a high frequency of dermatologist consultations in the country. Consequently, patients with conditions such as vitiligo and melasma are commonly diagnosed and treated within the community setting - the focus of this study. All interactions within the healthcare system are recorded in the patient’s electronic medical record, and the CHS database is continuously updated. The loss to follow-up is minimal (1-2% yearly).18 CHS data showed that the clinical variables, body mass index (BMI), and smoking data were missing for <2% of participants.19 This systematic data collection enables a robust longitudinal perspective on CHS members, supporting its value as a reliable source for epidemiological research.
Study population
The CHS database was reviewed for new cases of vitiligo diagnosed by board-certified dermatologists from 2002 to 2023. Diagnoses of melasma were included only if registered by a certified dermatologist. To establish a non-exposed comparison group, each patient was matched for age, sex, and primary-care clinic with up to five individuals without vitiligo. Comparison group individuals (comparators) were selected on the same date as the corresponding case diagnosis. Matching for the primary-care clinic helps account for unmeasured confounders, such as the availability of healthcare services in the residential environment, as well as composite variables, like socioeconomic status and ethnicity. Outcome measures were adjusted for demographic variables and potential confounders, including smoking, thyroid disorders, BMI, and treatment modalities (phototherapy, hormonal treatment, and hydroquinone). Hormonal agents curated from the dataset were validated by a certified gynaecologist specialising in fertility. The characteristics of the vitiligo patient database have been described in detail and can also be found in previous publications from our group.20,21
Statistical analysis
Patient characteristics were summarised by means and standard deviations (SDs) for continuous variables and percentages for categorical variables. Comparisons between study groups were made using χ2 or Fisher exact tests for categorical variables and t-tests or Mann-Whitney U tests for continuous variables, contingent upon the distribution of the data.
In the retrospective cohort study design, participants with pre-existing melasma were excluded. The exclusion of patients with vitiligo automatically led to the exclusion of their matched comparators. The incidence rates of melasma were computed as events per 1000 person-years. A stratified Cox proportional hazards model was used to assess the risk of development of melasma in patients with vitiligo compared to the comparison group.
Two separate multivariate models were developed: the first included all participants and was adjusted for demographic variables, BMI, smoking status, thyroid disorders, and phototherapy exposure. The second, limited to female participants, additionally incorporated pregnancy and hormonal treatment use as time-varying covariates. The cumulative incidence of melasma in patients with vitiligo and the comparison group was compared using the log-rank test.
In the nested case-control study design, participants with new-onset melasma were excluded. The odds of developing vitiligo in individuals with a prior history of melasma were calculated using a multivariate conditional logistic regression model adjusted for demographic factors, BMI, smoking status, thyroid disorders, and hydroquinone usage. As both phototherapy and hydroquinone are relevant confounders for the incidence of vitiligo and melasma, respectively, and due to the lack of granular data on cumulative dose or exposure intensity, sensitivity analyses were performed to minimise potential bias and confirm the robustness of our findings. We excluded patients and comparators treated with phototherapy in the cohort study and those treated with hydroquinone in the nested case-control design.
Statistical analyses were performed using R software (version 4.3.2), with a significance level of 0.05. All tests were two-tailed.
Results
Characteristics of the study population
The study population included 24,436 patients with vitiligo and 119,205 matched comparators. Mean (SD) patient age at diagnosis was 34.4 (21.8) years; 11,955 patients (48.9%) were male, and 17,440 (71.4%) were of Jewish ancestry. Compared to comparators, patients with vitiligo had a significantly lower prevalence of smoking (26.4% vs. 30.0%, P<0.001), lower mean (SD) BMI (25.4 [5.9] vs. 25.6 [6.3], P=0.008), and higher rates of both hypothyroidism (10.3% vs. 6.4%, P<0.001) and hyperthyroidism (1.5% vs. 1.1%, P<0.001). The demographic and clinical features of the study participants have been detailed in Table 1.
Characteristics |
Vitiligo (n=24,436) |
Matched comparators (n=119,205) |
P value | |
---|---|---|---|---|
Age (year), mean (SD) | 34.4 (21.8) | 34.2 (21.7) | 0.35 | |
Sex, n (%) | Male | 11,955 (48.9) | 58,307 (48.9) | 0.98 |
Female | 12,481 (51.1) | 60,898 (51.1) | ||
SES (score), mean (SD) | 5.11 (2.5) | 5.07 (2.5) | 0.008 | |
BMI (kg/m2), mean (SD) | 25.4 (5.9) | 25.6 (6.3) | 0.008 | |
Smoking, n (%) | 6,451 (26.4) | 35,738 (30.0) | <0.001 | |
Hyperthyroidism, n (%) | 357 (1.5) | 1,278 (1.1) | <0.001 | |
Hypothyroidism, n (%) | 2519 (10.3) | 7,648 (6.4) | <0.001 | |
Phototherapy, n (%) | NBUVB | 1794 (7.3) | 621 (0.5) | <0.001 |
PUVA | 322 (1.3) | 163 (0.1) | <0.001 | |
Hydroquinone, n (%) | 1231 (5.0) | 3,915 (3.3) | <0.001 | |
Hormonal treatment, n (%)a,b | 5747 (46.0) | 26,072 (42.8) | <0.001 | |
Pregnancy, n (%)a | Overall (≥1) | 2000 (16) | 9,543 (15.7) | 0.33 |
1 | 1017 (8.1) | 4,914 (8.1) | 0.78 | |
2-4 | 901 (7.2) | 4,223 (6.9) | 0.26 | |
≥4 | 82 (0.7) | 406 (0.7) | 0.95 |
aFemales (n=12,481 patients, 60,898 comparators). bIncluding oral contraceptive pills, hormone replacement therapy, gonadotropic stimulators. Significant values appear in bold. BMI: Body mass index, NBUVB: Narrowband ultraviolet B, PUVA: Psoralen and ultraviolet A, SD: Standard deviation, SES: Socioeconomic status. Bold values indicate statistically significant differences.
Risk of melasma in patients with vitiligo
After excluding patients (n=209) and comparators (n=1,605) with a pre-existing diagnosis of melasma, the retrospective cohort design included 24,227 patients with vitiligo and 117,600 comparators, thus maintaining a 1:5 ratio. The total follow-up time was 208,835 person-years for patients with vitiligo and 993,813 person-years for comparators. During the follow-up period, new-onset melasma was diagnosed in 288 patients with vitiligo and 872 comparators, yielding an incidence rate of 1.38 per 1,000 person-years among patients with vitiligo (95% CI 1.22-1.54) and 0.88 per 1,000 person-years among comparators (95% CI 0.84-0.96).
The crude risk of developing new-onset melasma was 60% greater among patients with vitiligo than comparators [HR 1.62, 95% CI 1.40-1.88, P<0.001; Figure 1 and Table 2]. On Cox proportional hazards model, after controlling for confounders including demographic variables, comorbidities, and phototherapy [presented in Suppl. Table 1], vitiligo was found to be a significant independent risk factor of melasma [adjusted HR 1.61, 95% CI 1.38-1.87, P<0.001; Table 3]. Stratified analyses revealed that pre-existing vitiligo was a predictor of new-onset melasma in females (HR 1.62, 95% CI 1.39-1.9, P<0.001) and in patients aged 20 years or older (P<0.001), as presented in Table 2.

- Cumulative incidence of melasma among patients with vitiligo and matched comparators. The shaded area surrounding the cumulative incidence curve represents the 95% confidence intervals. Bold values indicate statistically significant differences.
Subgroup | Melasma in patients with vitiligo n (%) (n=24,227)a | Melasma in comparators n (%) (n=117,600)a | HR (95%CI) | P value |
---|---|---|---|---|
All | 288 (1.2) | 872 (0.7) | 1.62 (1.40-1.88) | <0.001 |
Age (years) | ||||
<20 | 13 (0.2) | 64 (0.2) | 1.03 (0.53-1.99) | 0.93 |
20-40 | 183 (2.6) | 614 (1.8) | 1.49 (1.24-1.8) | <0.001 |
>40 | 92 (1) | 194 (0.4) | 2.2 (1.65-2.93) | <0.001 |
Sex | ||||
Male | 15 (0.1) | 34 (0.06) | 1.97 (0.99-3.9) | 0.05 |
Female | 273 (2.2) | 838 (1.4) | 1.62 (1.39-1.9) | <0.001 |
BMI (category) | ||||
Underweight | 10 (0.4) | 31 (0.3) | 1.32 (0.65-2.7) | 0.4 |
Normal | 147 (1.2) | 489 (0.8) | 1.53 (1.2-1.95) | <0.001 |
Overweight | 66 (1.2) | 180 (0.8) | 1.35 (0.83-2.18) | 0.2 |
Obese | 65 (1.4) | 172 (0.8) | 3.1 (1.84-5.17) | <0.001 |
Smoking | ||||
Yes | 74 (1.2) | 241 (0.7) | 1.7 (1.1-2.6) | 0.01 |
No | 214 (1.2) | 631 (0.8) | 1.6 (1.3-1.9) | <0.001 |
Hormonal treatmentb | ||||
Yes | 201 (3.7) | 615 (2.6) | 1.59 (1.31-1.92) | <0.001 |
No | 72 (1.0) | 273 (0.8) | 1.71 (1.19-2.50) | 0.004 |
aExcluding a pre-existing diagnosis of melasma. bFemale participants only. Significant values appear in bold. BMI: Body mass index, CI: Confidence interval, HR: Hazard ratio. Bold values indicate statistically significant differences.
Model type | Incident melasmaa | Incident vitiligob | ||
---|---|---|---|---|
HR (95% CI) | P value | OR (95% CI) | P value | |
Unadjusted | 1.62 (1.40-1.88) | <.001 | 1.57 (1.34-1.85) | <.001 |
Adjusted (all)c | 1.61 (1.38-1.87) | <.001 | 1.32 (1.12-1.55) | <.001 |
Adjusted (female only)d | 1.58 (1.35-1.86) | <.001 | None |
aRetrospective cohort design. bNested case-control design. cAdjustment includes demographics, body mass index, smoking status, thyroid disorders, and phototherapy exposure. dAdjustment includes pregnancy and hormonal treatment in addition to demographics, body mass index, smoking status, thyroid disorders, and phototherapy exposure. HR: Hazard Ratio, CI: Confidence Interval. Bold values indicate statistically significant differences.
In multivariate analysis limited tofemale patients hormones (birth control pills) and pregnancy relevant, including pregnancy and hormonal treatment as covariates, the HR remained significant [adjusted HR 1.58, 95% CI 1.35-1.86, P<0.001; Table 3]. The mean (SD) time from diagnosis of vitiligo, or the concordant matching date in comparators, to diagnosis of melasma was shorter in patients with vitiligo: 10.8 (4.3) years and 11.6 (4.1) years, respectively (P=0.01).
Association of pre-existing melasma with new-onset vitiligo
After excluding patients (n=288) and matched comparators (n=2,133) who did not develop melasma until the date of recruitment, the nested case-control study included 24,148 patients with vitiligo and 117,072 controls. The number of controls reflects the total matched comparators, excluding those who did not develop melasma prior to recruitment. The prevalence of pre-existing melasma was higher among the patients with vitiligo than controls (209 (0.9%) vs. 642 (0.5%), P<0.001). A history of melasma increased the odds of being diagnosed with subsequent vitiligo by 1.6-fold (OR 1.57, 95% CI 1.34-1.85, P<0.001). The mean (SD) interval between melasma and subsequent vitiligo diagnosis was comparable between patients with vitiligo and their matched controls: 5.0 (3.9) years and 5.0 (3.7) years, respectively (P=0.87).
Data stratification revealed that the presence of melasma predicted the diagnosis of vitiligo in patients aged ≥40 years (OR 1.81, 95% CI 1.48-2.29, P<0.001) regardless of gender, ethnicity, and smoking status. Melasma was associated with a 30% increase in the odds of developing vitiligo, even after adjusting for confounding factors, such as demographic variables, thyroid diseases, and hydroquinone treatment [adjusted OR 1.32, 95% CI 1.12-1.55, P<0.001; Table 3].
Features of patients with vitiligo and melasma compared to patients with vitiligo only
Compared to patients with vitiligo only, patients with coexistent vitiligo and melasma were significantly older at the onset of vitiligo (40.2 [12.9] vs. 34.3 [21.9] years; P<0.001), more likely to be female (94.4% vs. 50.2%; P<0.001), and had a higher frequency of hypothyroidism [15.7% vs, 10.2%; P<0.001; Table 4].
Characteristics |
Vitiligo and melasma (N=497) |
Isolated vitiligo (N=23,939) |
P value | |
---|---|---|---|---|
Age at diagnosis (year), mean (SD) | 40.2 (12.9) | 34.3 (21.9) | <0.001 | |
Sex, n (%) | Male | 28 (5.6) | 11,927 (49.8) | <0.001 |
Female | 469 (94.4) | 12,012 (50.2) | ||
SES (score), mean (SD) | 5.3 (2.6) | 5.1 (2.5) | 0.07 | |
BMI (kg/m2), mean (SD) | 25.9 (4.7) | 25.4 (5.9) | 0.03 | |
Smoking status, n (%) | Current | 66 (13.3) | 3429 (14.3) | 0.56 |
Past | 59 (11.9) | 2897 (12.1) | 0.95 | |
Never | 372 (74.9) | 17,613 (73.6) | 0.54 | |
Hyperthyroidism, n (%) | 8 (1.6) | 349 (1.5) | 0.71 | |
Hypothyroidism, n (%) | 78 (15.7) | 2441 (10.2) | <0.001 |
Significant values appear in bold. BMI: Body mass index, SD: Standard deviation, SES: Socioeconomic status. Bold values indicate statistically significant differences.
Sensitivity analyses
To validate the robustness of the data, sensitivity analyses were performed. In the retrospective cohort study, patients with vitiligo (n=1,886) and comparators (n=9,034) treated with phototherapy were excluded. The risk for melasma remained similar to the crude risk (HR 1.64, 95% CI: 1.40-1.92, P<0.001). In the nested case-control design, to confirm the association of melasma with incident vitiligo regardless of hydroquinone treatment, patients (n=1,101) and controls (n=8,840) treated with hydroquinone were excluded. The odds ratio for vitiligo remained significant (OR 1.37, 95% CI: 1.10-1.73, P=0.006).
Discussion
The current population-based epidemiologic study shows a bidirectional association between vitiligo and melasma. Vitiligo conferred a 60% increased risk of developing incident melasma, regardless of phototherapy and hormonal treatment, while patients with pre-existing melasma had 30% increased odds of subsequently developing vitiligo, regardless of hydroquinone treatment. Pre-existing melasma was more prevalent in patients with vitiligo than controls (0.9% vs. 0.5%). Patients with a dual diagnosis were mostly female, were older at the diagnosis of vitiligo, and had an increased frequency of hypothyroidism.
A potential underlying factor explaining the association of vitiligo and melasma may be the treatment modalities used; that is, the treatment applied for one condition may provoke the development of the other. NBUVB is considered the standard of care for vitiligo due to its superior efficacy and fewer adverse effects compared to psoralen UVA (PUVA), in addition to its ability to alleviate oxidative stress-induced damage to melanocytes.22 Melasma, however, is known to be aggravated by light exposure, and its treatment mainly relies on strict photoprotection.23
In the present study, the rate of utilisation of phototherapy was higher in patients with vitiligo (8.6%; 7.3% NB-UVB, 1.3% PUVA) than in comparators without vitiligo (0.6%; 0.5% NB-UVB, 0.1% PUVA). Using a retrospective cohort design, we found that phototherapy did not increase the risk of developing melasma [HR 1.2, 95% CI 0.80-1.85, P=0.40; Supplementary Table S1]. Sensitivity analysis excluding participants who did not receive phototherapy showed that the risk of developing melasma in patients with vitiligo was similar to the crude risk (HR 1.64, P<0.001). The lack of a contributory effect of UVB on the risk of development of melasma may be partly explained by accumulating evidence that visible light and UVA1 are the most significant triggers for melasma,24,25 whereas most of the patients with vitiligo in our cohort were treated with NBUVB.
Melasma is a multifactorial disorder where sex and sex hormones play a key pathogenetic role. Hormonal imbalances due to pregnancy, hormonal replacement therapy, and hormonal contraceptives stimulate melanogenesis.11 Consistent with the female predominance of melasma in the general population, in the present study, melasma was more prevalent in females than males among both patients (2.2% vs. 0.1%) and comparators (1.4% vs. 0.05%). However, on subgroup analysis, the risk of developing melasma was significant only in females with vitiligo compared to female comparators (HR 1.62, P<0.001).
Hormonal treatment was more prevalent in females with vitiligo than in female comparators (46.0% vs. 42.8%, P<0.001), while the number of pregnancies did not differ between the groups [Table 1]. On multivariate analysis, the risk for developing melasma was higher among female patients with vitiligo independently of their hormone treatment status [Table 3].
Hydroquinone, especially when used in a triple combination compound with a mild-potency steroid and a retinoid, is considered the gold standard of melasma treatment.23,26 Hydroquinone is a phenolic compound with antioxidant properties that disrupts melanogenesis by inhibiting tyrosinase, which can also cause selective damage to melanocytes. The lightening effect typically takes months to become visible, necessitating long-term use.23 There are only a few reports describing leukoderma following hydroquinone use,27,28 in contrast to the expected depigmentation seen with hydroquinone’s structurally related chemical, monobenzyl ether of hydroquinone. Therefore, hydroquinone treatment is currently considered safe for patients with vitiligo, though its use should be evaluated on a case-by-case basis.29
In the present cohort, hydroquinone was used significantly more frequently by patients than comparators (5% vs. 3.3%, P<0.001). It is possible that it was applied as an additive to “smoothen” the distinctive appearance of vitiligo lesions.29 Nevertheless, although hydroquinone was significantly associated with an increased odds of development of vitiligo in patients with melasma (OR 1.54, P<0.001), on both sensitivity and multivariate analyses, melasma was associated with vitiligo independently of hydroquinone treatment status.
Autoimmune thyroid disease (both hypothyroidism and hyperthyroidism) is a well-recognised comorbidity of vitiligo.30 It has also been identified as a provoking factor of melasma.12,31 As expected, in the present cohort, both hypothyroidism and hyperthyroidism were more prevalent among patients with vitiligo [Table 1]. In our retrospective cohort design, both hypothyroidism and hyperthyroidism were associated with an increased risk of developing melasma [Supplementary Table S1], and in the nested case-control design, both were associated with increased odds of developing vitiligo in cases of pre-existing melasma [Supplementary Table S2]. These findings suggest that autoimmune thyroid diseases should be considered when investigating the association between these two chronic pigmentary disorders. Nonetheless, in our multivariate model, after adjusting for hypothyroidism and hyperthyroidism along with other relevant clinical variables, the independent risk of developing melasma in patients with vitiligo remained nearly unchanged (HR 1.6) in both the entire cohort and among female patients. In the nested case-control study, adjustment weakened the independent association between melasma and subsequent vitiligo, although it remained significant (adjusted OR 1.32, P<0.001).
Vitiligo and melasma are considered phenotypically opposite ends of the pigmentation spectrum, with a complete loss of melanocytes (vitiligo) at one pole and increased melanin deposition by hyper functional melanocytes (melasma) at the other pole. Nevertheless, the two relatively common acquired pigmentation disorders share several pathogenetic links, such as oxidative stress, which might explain their connection.11 Specifically, both external and internal stimuli can lead to the generation of excess reactive oxygen species in the skin. External factors include UV radiation and air pollution, and intrinsic factors involve processes such as melanogenesis in melanocytes.11,32-35
Given that both vitiligo and melasma are characterised by an imbalance in oxidative stress, triggering melanocyte destruction in vitiligo and melanogenesis in melasma may help explain the findings that having one condition increases susceptibility to the other. Antioxidant treatments could potentially treat or prevent both conditions. Polypodium leucotomas has shown benefits in both vitiligo and melasma due to its antioxidant and photoprotective properties.36,37
This study directly investigates the association between vitiligo and melasma by evaluating the bidirectional relationship through both risk estimates (retrospective cohort) and odds ratios (nested case-control). To our knowledge, this bidirectional association has not been previously reported. Previous retrospective studies examined the effects of treatments for one condition on the other.16,17 In one study, using tranexamic acid for melasma alongside phototherapy for vitiligo in 32 patients resulted in an 80% improvement in melasma without worsening vitiligo.16 Another study evaluated NBUVB phototherapy’s impact on vitiligo repigmentation in two cohorts: one with only vitiligo and one with a dual diagnosis. It found that vitiligo lesions improved more in patients with dual diagnosis for facial and limb lesions, while truncal lesions showed better repigmentation in the vitiligo-only group.17
Strengths
The study’s key strengths are a large cohort size and dermatologist-confirmed diagnoses, enhancing statistical power and validity.
Limitations
This study is limited by the lack of data on several important clinical parameters, including disease extent, severity (as assessed by validated instruments such as the Vitiligo Area Scoring Index [VASI] and the Melasma Area and Severity Index [MASI]), vitiligo activity status, lesion distribution, and co-localisation with facial melasma. These details were unavailable due to the exclusive use of computerised datasets, which did not capture comprehensive clinical evaluations. The study also did not account for skin phototype and natural sun exposure, both significant factors in melasma development, and the use of over-the-counter melasma treatments, which could influence vitiligo development. Nevertheless, sensitivity analysis and adjustments for putative covariates confirmed the independent bidirectional association between vitiligo and melasma, with primary-care clinic matching helping to control for differences in healthcare access and to ensure comparable environmental exposures. Future prospective studies could address these limitations and enhance the generalisability of the findings across diverse ethnic and population groups. They would also allow for better accounting of residual confounders that could not be adequately addressed due to the retrospective nature of the current study.
Conclusion
This large-scale study demonstrated a bidirectional association between vitiligo and melasma. Patients with vitiligo are at increased risk of developing melasma, and patients with melasma are at increased odds of developing vitiligo. Dermatologists should be aware of this association for the identification of subgroups at risk. Further prospective studies are needed to explore potential treatments for patients with a dual diagnosis.
Ethical approval
The research/study was approved by the Institutional CHS Institutional Review Board, (approval number COM2-0212-17) number 0212-17-COM, dated 2024.
Declaration of patient consent
Patient’s consent not required as there are no patients in this study.
Financial support and sponsorship
Nil.
Conflicts of interest
Prof. Harris is a consultant for AbbVie, Aldena, Almiral, Avita, Biologics MD, Genzyme/Sanofi, Granular Therapeutics, Incyte, Klirna, LEO Pharma, Matchpoint Therapeutics, Merck, NIRA Biosciences, Pfizer, Sun Pharmaceuticals, Temprian Therapeutics, Vimela Therapeutics, and Vividion Therapeutics. He is an investigator for Genzyme/Sanofi, Incyte, LEO Pharma, Pfizer, and Sun Pharmaceuticals; and holds equity stock (founder) in Aldena, Klirna, NIRA Biosciences, and Vimela Therapeutics. Prof. Arnon Cohen served as a consultant, advisor, or speaker for AbbVie, Amgen, Boehringer Ingelheim, Dexcel Pharma, Janssen, Kamedis, Lilly, Neopharm, Novartis, Perrigo, Pfizer, Rafa, Samsung Bioepis, Sanofi, Sirbal and Taro. The remaining authors declare no conflict of interest.
Use of artificial intelligence (AI)-assisted technology for manuscript preparation
The authors confirm that there was no use of artificial intelligence (AI)-assisted technology for assisting in the writing or editing of the manuscript and no images were manipulated using AI.
References
- The role of oxidative stress in vitiligo: An update on its pathogenesis and therapeutic implications. Cells. 2023;12:936.
- [CrossRef] [Google Scholar]
- Vitiligo: Mechanisms of pathogenesis and treatment. Annu Rev Immunol. 2020;38:621-48.
- [CrossRef] [Google Scholar]
- Maintenance therapy of adult vitiligo with 0.1% tacrolimus ointment: A randomized, double blind, placebo-controlled study. J Invest Dermatol. 2015;135:970-4.
- [Google Scholar]
- Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the international vitiligo task force part 1: Towards a new management algorithm. J Eur Acad Dermatol Venereol. 2023;37:2173-84.
- [Google Scholar]
- Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the international vitiligo task force-part 2: Specific treatment recommendations. J Eur Acad Dermatol Venereol. 2023;37:2185-9.
- [Google Scholar]
- Current and emerging treatments for vitiligo. J Am Acad Dermatol. 2017;77:17-29.
- [CrossRef] [Google Scholar]
- Phototherapy for vitiligo: A narrative review on the clinical and molecular aspects, and recent literature. Photodermatol Photoimmunol Photomed. 2024;40:e12968.
- [CrossRef] [Google Scholar]
- The pathogenesis of melasma and implications for treatment. J Cosmet Dermatol. 2021;20:3432-45.
- [CrossRef] [Google Scholar]
- Histochemical and immunohistochemical study in melasma: Evidence of damage in the basal membrane. Am J Dermatopathol. 2011;33:291-5.
- [Google Scholar]
- Assessment and comparison of quality of life in patients with melasma and vitiligo. Kathmandu Univ Med J (KUMJ). 2019;17:114-8.
- [Google Scholar]
- Feasibility of oral tranexamic acid for vitiligo patients with melasma. Dermatol Ther. 2021;34:e15047.
- [CrossRef] [Google Scholar]
- Response to narrow-band UVB--vitiligo-melasma versus vitiligo: a comparative study. Am J Clin Dermatol. 2011;12:127-32.
- [Google Scholar]
- BNT162b2 mRNA covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384:1412-23.
- [CrossRef] [Google Scholar]
- Association of opioid use disorder with healthcare utilization and cost in a public health system. Addiction. 2022;117:2880-6.
- [CrossRef] [Google Scholar]
- Vitiligo and systemic sclerosis: Are they associated?- lessons from a population-based study. Australas J Dermatol. 2023;64:e65-71.
- [Google Scholar]
- A bidirectional autoimmune cluster between vitiligo and rheumatoid arthritis: A large-scale population-based study. Arch Dermatol Res. 2024;316
- [CrossRef] [Google Scholar]
- UVB phototherapy in the treatment of vitiligo: State of the art and clinical perspectives. Photodermatol Photoimmunol Photomed. 2022;38:215-23.
- [Google Scholar]
- Melasma, a photoaging disorder. Pigment Cell Melanoma Res. 2018;31:461-5.
- [CrossRef] [Google Scholar]
- Photoprotection: Current developments and controversies. J Eur Acad Dermatol Venereol. 2024;38 Suppl 5:12-20.
- [CrossRef] [Google Scholar]
- The treatment of melasma: A review of clinical trials. J Am Acad Dermatol. 2006;55:1048-65.
- [CrossRef] [Google Scholar]
- Chemical leukoderma due to hydroquinone: An unusual phenomenon. Indian J Dermatol Venereol Leprol. 2019;85:567.
- [CrossRef] [Google Scholar]
- Diffuse facial leukoderma secondary to localized use of hydroquinone. Cureus. 2024;16:e67751.
- [CrossRef] [Google Scholar]
- The prevalence of thyroid disorders in patients with vitiligo: A systematic review and meta-analysis. Front Endocrinol (Lausanne). 2019;9:803.
- [CrossRef] [Google Scholar]
- Melasma and thyroid disorders: A systematic review and meta-analysis. Int J Dermatol. 2019;58:1231-8.
- [Google Scholar]
- The role of oxidative stress in the pathogenesis of vitiligo: A culprit for melanocyte death. Oxid Med Cell Longev. 2022;2022:8498472.
- [CrossRef] [Google Scholar]
- Oxidative stress-induced IL-15 trans-presentation in keratinocytes contributes to CD8+ T cells activation via JAK-STAT pathway in vitiligo. Free Radic Biol Med. 2019;139:80-91.
- [Google Scholar]
- Co-localization of inducible nitric oxide synthase and phosphorylated akt in the lesional skins of patients with melasma. J Dermatol. 2009;36:10-6.
- [Google Scholar]
- Oxidative stress status in patients with melasma. Cutan Ocul Toxicol. 2014;33:212-7.
- [Google Scholar]
- The impact of antioxidants on vitiligo and melasma: A scoping review and meta-analysis. Antioxidants (Basel). 2023;12:2082.
- [CrossRef] [Google Scholar]
- Polypodium leucotomos as an adjunct treatment of pigmentary disorders. J Clin Aesthet Dermatol. 2014;7:13-7.
- [Google Scholar]